104
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      PROCalcitonin-based algorithm for antibiotic use in Acute Pancreatitis (PROCAP): study protocol for a randomised controlled trial

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Differentiating infection from inflammation in acute pancreatitis is difficult, leading to overuse of antibiotics. Procalcitonin (PCT) measurement is a means of distinguishing infection from inflammation as levels rise rapidly in response to a pro-inflammatory stimulus of bacterial origin and normally fall after successful treatment. Algorithms based on PCT measurement can differentiate bacterial sepsis from a systemic inflammatory response. The PROCalcitonin-based algorithm for antibiotic use in Acute Pancreatitis (PROCAP) trial tests the hypothesis that a PCT-based algorithm to guide initiation, continuation and discontinuation of antibiotics will lead to reduced antibiotic use in patients with acute pancreatitis and without an adverse effect on outcome.

          Methods

          This is a single-centre, randomised, controlled, single-blind, two-arm pragmatic clinical and cost-effectiveness trial. Patients with a clinical diagnosis of acute pancreatitis will be allocated on a 1:1 basis to intervention or standard care. Intervention will involve the use of a PCT-based algorithm to guide antibiotic use. The primary outcome measure will be the binary outcome of antibiotic use during index admission. Secondary outcome measures include: safety non-inferiority endpoint all-cause mortality; days of antibiotic use; clinical infections; new isolates of multiresistant bacteria; duration of inpatient stay; episode-related mortality and cause; quality of life (EuroQol EQ-5D); and cost analysis. A 20% absolute change in antibiotic use would be a clinically important difference. A study with 80% power and 5% significance (two-sided) would require 97 patients in each arm (194 patients in total): the study will aim to recruit 200 patients. Analysis will follow intention-to-treat principles.

          Discussion

          When complete, PROCAP will be the largest randomised trial of the use of a PCT algorithm to guide initiation, continuation and cessation of antibiotics in acute pancreatitis. PROCAP is the only randomised trial to date to compare standard care of acute pancreatitis as defined by the International Association of Pancreatology/American Pancreatic Association guidelines to patients having standard care but with all antibiotic prescribing decisions based on PCT measurement.

          Trial registration

          International Standard Randomised Controlled Trial Number, ISRCTN50584992. Registered on 7 February 2018.

          Electronic supplementary material

          The online version of this article (10.1186/s13063-019-3549-3) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: not found
          • Article: not found

          Antibiotic-resistant bugs in the 21st century--a clinical super-challenge.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms.

            Previous randomized controlled trials suggest that using clinical algorithms based on procalcitonin levels, a marker of bacterial infections, results in reduced antibiotic use without a deleterious effect on clinical outcomes. However, algorithms differed among trials and were embedded primarily within the European health care setting. Herein, we summarize the design, efficacy, and safety of previous randomized controlled trials and propose adapted algorithms for US settings. We performed a systematic search and included all 14 randomized controlled trials (N = 4467 patients) that investigated procalcitonin algorithms for antibiotic treatment decisions in adult patients with respiratory tract infections and sepsis from primary care, emergency department (ED), and intensive care unit settings. We found no significant difference in mortality between procalcitonin-treated and control patients overall (odds ratio, 0.91; 95% confidence interval, 0.73-1.14) or in primary care (0.13; 0-6.64), ED (0.95; 0.67-1.36), and intensive care unit (0.89; 0.66-1.20) settings individually. A consistent reduction was observed in antibiotic prescription and/or duration of therapy, mainly owing to lower prescribing rates in low-acuity primary care and ED patients, and shorter duration of therapy in moderate- and high-acuity ED and intensive care unit patients. Measurement of procalcitonin levels for antibiotic decisions in patients with respiratory tract infections and sepsis appears to reduce antibiotic exposure without worsening the mortality rate. We propose specific procalcitonin algorithms for low-, moderate-, and high-acuity patients as a basis for future trials aiming at reducing antibiotic overconsumption.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis: systematic review.

              Many studies have evaluated serum levels of procalcitonin (PCT) as a predictor in the development of severe acute pancreatitis (SAP) and infected pancreatic necrosis (IPN). This study assesses the value of PCT as a marker of development of SAP and IPN. Medline, Web of Science, the Cochrane clinical trials register, and international conference proceedings were searched systematically for prospective studies, which evaluated the usefulness of PCT as a marker of SAP and IPN. The sensitivity, specificity, and diagnostic odds ratios (DORs) were calculated for each study, and the study quality and heterogeneity among the studies were evaluated. Twenty-four of 59 studies identified were included in data extraction. The sensitivity and specificity of PCT for development of SAP were 0.72 and 0.86, respectively (area under the curve [AUC] = 0.87; DOR = 14.9; 95% confidence interval [CI] = 5.6-39.8), albeit with a significant degree of heterogeneity (Q = 28.56, P 0.5 ng/mL (AUC = 0.88, 32.8; 95% CI = 10.1-106.6) were included. Serum measurements of PCT may be valuable in predicting the severity of acute pancreatitis and the risk of developing infected pancreatic necrosis.
                Bookmark

                Author and article information

                Contributors
                44-(0)-161-276-8886 , ajith.siriwardena@mft.nhs.uk
                santhalingam.jegatheeswaran@mft.nhs.uk
                j.mason@warwick.ac.uk
                baltmin@gmail.com
                anthony.chan@mft.nhs.uk
                aali.sheen@mft.nhs.uk
                derek.o'reilly@mft.nhs.uk
                saurabh.jamdar@mft.nhs.uk
                rahul.deshpande@mft.nhs.uk
                nicola.deliguoricarino@mft.nhs.uk
                thomas.satyadas@mft.nhs.uk
                ahmed.qamruddin@mft.nhs.uk
                katherine.hayden@mft.nhs.uk
                m.parker@mft.nhs.uk
                john.butler@mft.nhs.uk
                azita.rajai@mft.nhs.uk
                ben.mcintyre@mft.nhs.uk
                Journal
                Trials
                Trials
                Trials
                BioMed Central (London )
                1745-6215
                29 July 2019
                29 July 2019
                2019
                : 20
                : 463
                Affiliations
                [1 ]ISNI 0000 0004 0641 2823, GRID grid.419319.7, Regional Hepato-Pancreato-Biliary Unit, , Manchester Royal Infirmary, ; Oxford Road, Manchester, M13 9WL UK
                [2 ]ISNI 0000000121662407, GRID grid.5379.8, Faculty of Biology, Health and Life Sciences, , University of Manchester, Manchester Academic Health Sciences Centre, ; Manchester, UK
                [3 ]ISNI 0000 0000 8809 1613, GRID grid.7372.1, Warwick Medical School, , University of Warwick, ; Coventry, UK
                [4 ]ISNI 0000 0001 0790 5329, GRID grid.25627.34, Centre for Biomedicine, , Manchester Metropolitan University, ; Manchester, UK
                [5 ]ISNI 0000 0004 0641 2823, GRID grid.419319.7, Department of Microbiology, , Manchester Royal Infirmary, ; Oxford Road, Manchester, M13 9WL UK
                [6 ]ISNI 0000 0004 0641 2823, GRID grid.419319.7, Department of Clinical Biochemistry, , Manchester Royal Infirmary, ; Oxford Road, Manchester, M13 9WL UK
                [7 ]ISNI 0000 0004 0641 2823, GRID grid.419319.7, Critical Care Unit, , Manchester Royal Infirmary, ; Oxford Road, Manchester, M13 9WL UK
                [8 ]ISNI 0000 0004 0641 2823, GRID grid.419319.7, Pharmacy Department, , Manchester Royal Infirmary, ; Oxford Road, Manchester, M13 9WL UK
                Author information
                http://orcid.org/0000-0001-8004-0560
                Article
                3549
                10.1186/s13063-019-3549-3
                6664733
                31358032
                a406d08f-10b4-4ecc-b4b4-9a0e0b34eecc
                © The Author(s). 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 26 December 2018
                : 29 June 2019
                Categories
                Study Protocol
                Custom metadata
                © The Author(s) 2019

                Medicine
                acute pancreatitis,antibiotics,procalcitonin
                Medicine
                acute pancreatitis, antibiotics, procalcitonin

                Comments

                Comment on this article